The “groundbreaking drug” offers new hope to patients in the early stages.
A US drug company, Biogen, has created the drug, aducanumab, which would be the first treatment to “reduce the clinical decline” of patients in the early stages of Alzheimer’s disease if approved.
The company said it will soon seek regulatory approval for the drug in the US as reported by BBC.
In March 2019, Biogen had discontinued their work on the drug after disappointing trial results. But new analysis showed that higher doses of aducanumab can provide a significant benefit to patients.
Hilary Evans from Alzheimer’s Research UK said: “People affected by Alzheimer’s have waited a long time for a life-changing new treatment and this exciting announcement offers new hope that one could be in sight.”
Talking about the hope aducanumab brings with it, Prof Bart De Strooper, Director of the UK Dementia Research Institute at University College London, said: “It is fantastic to hear of these new positive results emerging from the aducanumab trials. We currently have no effective treatments to slow or halt the progression of Alzheimer’s disease and I hope this signifies a turning point.”
To read the original article, click here.